Squib

Bristol Myers Squibb Completes Sale of Manufacturing Facility in Couvet, Switzerland

Retrieved on: 
Tuesday, August 3, 2021
Other Manufacturing, Research, Manufacturing, Other Health, Biotechnology, General Health, Pharmaceutical, Health, Science, Other Science, Life sciences, Industry economics), Companies, Bristol-Myers Squibb, Bristol Myers Squibb, WuXi AppTec, Squib

Bristol Myers Squibb (NYSE: BMY) today announced that it has completed the previously announced sale of its manufacturing facility in Couvet, Switzerland, to WuXi STA, a subsidiary of WuXi AppTec.

Key Points: 
  • Bristol Myers Squibb (NYSE: BMY) today announced that it has completed the previously announced sale of its manufacturing facility in Couvet, Switzerland, to WuXi STA, a subsidiary of WuXi AppTec.
  • The divestiture is part of Bristol Myers Squibbs ongoing evolution of its manufacturing network to support its product portfolio.
  • Switzerland remains an important strategic location for the Company, and Bristol Myers Squibb expects to maintain a strong presence in the country.
  • For more information about Bristol Myers Squibb, visit us at BMS.com or follow us on LinkedIn , Twitter , YouTube , Facebook and Instagram .

Arena Pharmaceuticals Appoints Doug Manion, M.D., F.R.C.P. (C), as Executive Vice President of Research & Development

Retrieved on: 
Monday, July 19, 2021
Biotechnology, Pharmaceutical, Health, Cardiology, Bristol Myers Squibb, Life sciences, Companies, Squib, Corporate title, Articles

(C), as Executive Vice President of Research & Development, reporting to Amit D. Munshi, President and CEO of Arena.

Key Points: 
  • (C), as Executive Vice President of Research & Development, reporting to Amit D. Munshi, President and CEO of Arena.
  • "Doug has leadership experience across all aspects of research and development, as well as extensive international experience, which will guide Arena R&D as we continue to grow and progress our portfolio."
  • Previously Dr. Manion was Senior Vice President, Head of Specialty Development and Head R&D Japan and China at Bristol-Myers Squibb.
  • Arena disclaims any intent or obligation to update these forward-looking statements, other than as may be required under applicable law.

Letter from Gatemore Capital Management LLP to Sensyne Health PLC

Retrieved on: 
Monday, July 19, 2021
Capital market, Squib

As you are aware, Gatemore Capital Management LLP ("Gatemore" or "we") manages the Gatemore Special Opportunities Fund, which as of today, has an economic interest of approximately 5.9% in Sensyne Health plc ("Sensyne" or the "Company").

Key Points: 
  • As you are aware, Gatemore Capital Management LLP ("Gatemore" or "we") manages the Gatemore Special Opportunities Fund, which as of today, has an economic interest of approximately 5.9% in Sensyne Health plc ("Sensyne" or the "Company").
  • We have been enthusiastic investors in Sensyne since January 2020, and have appreciated our collaborative engagement with both the Board of Directors and Management.
  • Sensyne already has such projects underway with Roche, Bayer, Bristol Myers Squibb and others.
  • It is well-recognised that the US capital markets are a better venue for growth companies such as Sensyne.

Letter from Gatemore Capital Management LLP to Sensyne Health PLC

Retrieved on: 
Monday, July 19, 2021
Capital market, Squib

As you are aware, Gatemore Capital Management LLP ("Gatemore" or "we") manages the Gatemore Special Opportunities Fund, which as of today, has an economic interest of approximately 5.9% in Sensyne Health plc ("Sensyne" or the "Company").

Key Points: 
  • As you are aware, Gatemore Capital Management LLP ("Gatemore" or "we") manages the Gatemore Special Opportunities Fund, which as of today, has an economic interest of approximately 5.9% in Sensyne Health plc ("Sensyne" or the "Company").
  • We have been enthusiastic investors in Sensyne since January 2020, and have appreciated our collaborative engagement with both the Board of Directors and Management.
  • Sensyne already has such projects underway with Roche, Bayer, Bristol Myers Squibb and others.
  • It is well-recognised that the US capital markets are a better venue for growth companies such as Sensyne.

Agenus Closes $200M Upfront BMS Collaboration and Announces FDA Acceptance of IND for Partnered Anti-TIGIT Bispecific Antibody, AGEN1777

Retrieved on: 
Tuesday, July 6, 2021
Life sciences, Immune system, Medical specialties, Branches of biology, Bristol-Myers Squibb, Bristol Myers Squibb, Agenus, Cancer immunotherapy, Monoclonal antibodies, Natural killer cell, Squib, Compugen

AGEN1777 is an Fc-enhanced antibody in late preclinical development designed to target major inhibitory receptors expressed on T and NK cells to improve anti-tumor activity.

Key Points: 
  • AGEN1777 is an Fc-enhanced antibody in late preclinical development designed to target major inhibitory receptors expressed on T and NK cells to improve anti-tumor activity.
  • Bristol Myers Squibb intends to advance the research and development of AGEN1777 in immuno-oncology for high priority tumor indications including non-small cell lung cancer.
  • Under the terms of the agreement with Bristol Myers Squibb, Agenus receives a $200 million upfront payment in connection with the closing.
  • Bristol Myers Squibb will become solely responsible for the development and any subsequent commercialization of AGEN1777 and its related products worldwide.

Eisai, Bristol Myers Squibb Enter Into Global Strategic Collaboration for Eisai's MORAb-202 Antibody Drug Conjugate

Retrieved on: 
Friday, June 18, 2021
Life sciences, Monoclonal antibodies, Bristol-Myers Squibb, Bristol Myers Squibb, Companies, Biotechnology, Squib, Lulizumab pegol

Bristol Myers Squibb will be solely responsible for developing and commercializing the drug in regions outside of the collaboration territories.

Key Points: 
  • Bristol Myers Squibb will be solely responsible for developing and commercializing the drug in regions outside of the collaboration territories.
  • The parties will share profits, research and development and commercialization costs in the collaboration territories and Bristol Myers Squibb will pay Eisai a royalty on sales outside of the collaboration territories.
  • Bristol Myers Squibb is expected to book sales of MORAb-202 in the United States and Canada.
  • Our collaboration with Bristol Myers Squibb will accelerate the development of MORAb-202 with the goal of bringing a potentially impactful treatment option to patients globally."

Eisai and Bristol Myers Squibb Enter Into Global Strategic Collaboration for Eisai’s MORAb-202 Antibody Drug Conjugate

Retrieved on: 
Thursday, June 17, 2021
Biotechnology, Health, Pharmaceutical, Clinical trials, Oncology, Life sciences, Drugs, Monoclonal antibodies, Orphan drugs, Health care, Antineoplastic drugs, Bristol Myers Squibb, Eribulin, Eisai, Squib, Bristol-Myers Squibb, Eisai Co., Ltd., Bristol Myers Squibb, MORAb-202, EISAI CO., LTD., BRISTOL MYERS SQUIBB, MORAB-202

Eisai Co., Ltd. and Bristol-Myers Squibb Company (NYSE: BMY) announced today that the companies have entered into an exclusive global strategic collaboration agreement for the co-development and co-commercialization of MORAb-202, an antibody drug conjugate (ADC).

Key Points: 
  • Eisai Co., Ltd. and Bristol-Myers Squibb Company (NYSE: BMY) announced today that the companies have entered into an exclusive global strategic collaboration agreement for the co-development and co-commercialization of MORAb-202, an antibody drug conjugate (ADC).
  • MORAb-202 is Eisais first ADC and combines Eisais in house developed anti-folate receptor alpha (FR) antibody, and Eisais anticancer agent eribulin, using an enzyme cleavable linker.
  • Bristol Myers Squibb will be solely responsible for developing and commercializing the drug in regions outside of the collaboration territories.
  • The parties will share profits, research and development and commercialization costs in the collaboration territories and Bristol Myers Squibb will pay Eisai a royalty on sales outside of the collaboration territories.

Bristol Myers Squibb Announces Dividend

Retrieved on: 
Thursday, June 17, 2021
Biotechnology, Pharmaceutical, Health, Bristol Myers Squibb, Life sciences, Industry economics), Squib, Companies, Dividend, Bristol-Myers Squibb, Monoclonal antibodies

Bristol Myers Squibb (NYSE: BMY) today announced that its Board of Directors has declared a quarterly dividend of forty-nine cents ($0.49) per share on the $.10 par value common stock of the company.

Key Points: 
  • Bristol Myers Squibb (NYSE: BMY) today announced that its Board of Directors has declared a quarterly dividend of forty-nine cents ($0.49) per share on the $.10 par value common stock of the company.
  • The dividend is payable on August 2, 2021 to stockholders of record at the close of business on July 2, 2021.
  • Bristol Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases.
  • For more information about Bristol Myers Squibb, visit us at BMS.com or follow us on LinkedIn , Twitter , YouTube , Facebook , and Instagram .

Bristol Myers Squibb and GRYT Health Evolve Virtual Patient Advocacy Experience

Retrieved on: 
Thursday, June 10, 2021
Oncology, Health, Technology, Software, Clinical trials, Pharmaceutical, Biotechnology, Bristol Myers Squibb, Squib, Advocacy, BMS, Life sciences, Companies, Articles

Today, Bristol Myers Squibb (NYSE: BMY) and GRYT Health unveiled the Advocacy Exchange, an evolution of the existing COVID Advocacy Exchange, an enduring community built to support patient advocacy organizations by providing access to educational resources, encouraging ongoing dialogue, and sharing best practices among participants.

Key Points: 
  • Today, Bristol Myers Squibb (NYSE: BMY) and GRYT Health unveiled the Advocacy Exchange, an evolution of the existing COVID Advocacy Exchange, an enduring community built to support patient advocacy organizations by providing access to educational resources, encouraging ongoing dialogue, and sharing best practices among participants.
  • While the pandemic and its effects continue to be felt, we are moving into a new chapter with The Exchange, said Cathy Traz, Executive Director, Patient Advocacy, Bristol Myers Squibb.
  • As we engage in conversations with the global patient advocacy community, we hope the Advocacy Exchange will allow us to create lasting relationships, said David Craig, GRYT Health Co-Founder and CEO.
  • For more information about Bristol Myers Squibb, visit us at BMS.com or follow us on LinkedIn , Twitter , YouTube , Facebook and Instagram .

Bristol Myers Squibb to Report Results for Second Quarter 2021 on July 28, 2021

Retrieved on: 
Thursday, June 10, 2021
Research, Medical Supplies, Clinical trials, Biotechnology, Health, Pharmaceutical, General Health, Science, Oncology, Bristol Myers Squibb, Life sciences, Companies, Squib, Bristol-Myers Squibb, Industry economics), Monoclonal antibodies, Jeremy Levin

Bristol Myers Squibb (NYSE:BMY) will announce results for the second quarter of 2021 on Wednesday, July 28, 2021.

Key Points: 
  • Bristol Myers Squibb (NYSE:BMY) will announce results for the second quarter of 2021 on Wednesday, July 28, 2021.
  • ET on July 28, 2021, company executives will review financial results and address inquiries from investors and analysts.
  • Bristol Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases.
  • For more information about Bristol Myers Squibb, visit us at BMS.com or follow us on LinkedIn , Twitter , YouTube , Facebook , and Instagram .